TSVT — 2Seventy Bio Share News
0.000.00%
Last trade - 00:00- $265.62m
- $95.24m
- $37.86m
U.S. STOCKS ON THE MOVE-Zions Bancorp, Neurocrine Biosciences, Beauty Health
US FDA uncertain about supply timeline of Novo Nordisk's weight loss drug
U.S. STOCKS ON THE MOVE-Guardforce AI, 2seventy Bio, GoDaddy
2seventy bio to lay off 40% of workforce (updated)
2seventy bio rises on restructuring changes including job cuts
Brief: 2Seventy Bio Announces Strategic Restructuring To Prioritize Growth Of Abecma, Streamline Pipeline Advancement And Preserve Financial Runway
2seventy bio CEO to step down, plans job cuts
Brief: 2Seventy Bio And JW Therapeutics Announce Intent To Expand Strategic Partnership To Accelerate The Research And Development Of T Cell-Based Immunotherapies & Autoimmune Therapies
Brief: 2Seventy Bio Q2 Basic EPS USD -0.83
U.S. RESEARCH ROUNDUP-New York Community Bancorp, Owens Corning, Perficient
U.S. STOCKS ON THE MOVE-Netflix, Nova Lifestyle, Nvidia
U.S. STOCKS ON THE MOVE-BlackRock, IPG Photonics, Estee Lauder
U.S. STOCKS ON THE MOVE-Amneal Pharma, 2seventy bio, Blue Water Biotech
U.S. STOCKS ON THE MOVE-Advanced Micro Devices, NextDecade, Agile Therapeutics
2SeventyBio's partner pauses cancer therapy study after patient death (updated)
2seventy bio down as partner pauses blood cancer therapy study
2SeventyBio's partner pauses early-stage cancer study
Brief: 2Seventy Bio Presents Late-Breaking Results For SC-Daric33
Brief: 2Seventy Bio BBT369 & CBLB Gene Edited Autologous Car T For Non-Hodgkin Lymphoma Showed Edit-Driven T Cell Activity In Multiple Preclinical Models